0001654954-20-000270.txt : 20200110 0001654954-20-000270.hdr.sgml : 20200110 20200110141335 ACCESSION NUMBER: 0001654954-20-000270 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200108 FILED AS OF DATE: 20200110 DATE AS OF CHANGE: 20200110 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: van der Velden Peter CENTRAL INDEX KEY: 0001778046 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37619 FILM NUMBER: 20520568 MAIL ADDRESS: STREET 1: C/O EDESA BIOTECH INC. STREET 2: 100 SPY COURT CITY: MARKHAM STATE: A6 ZIP: L3R 5H6 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lumira Capital Investment Management Inc. CENTRAL INDEX KEY: 0001702636 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37619 FILM NUMBER: 20520569 BUSINESS ADDRESS: STREET 1: 141 ADELAIDE STREET WEST STREET 2: SUITE 770 CITY: TORONTO STATE: A6 ZIP: M5H 3L5 BUSINESS PHONE: 416-213-4223 MAIL ADDRESS: STREET 1: 141 ADELAIDE STREET WEST STREET 2: SUITE 770 CITY: TORONTO STATE: A6 ZIP: M5H 3L5 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Edesa Biotech, Inc. CENTRAL INDEX KEY: 0001540159 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 100 SPY COURT CITY: MARKHAM STATE: A6 ZIP: L3R 5H6 BUSINESS PHONE: (905) 475-1234 MAIL ADDRESS: STREET 1: 100 SPY COURT CITY: MARKHAM STATE: A6 ZIP: L3R 5H6 FORMER COMPANY: FORMER CONFORMED NAME: Stellar Biotechnologies, Inc. DATE OF NAME CHANGE: 20120120 4 1 section16.xml PRIMARY DOCUMENT X0306 4 2020-01-08 0001540159 Edesa Biotech, Inc. EDSA 0001778046 van der Velden Peter C/O EDESA BIOTECH INC. 100 SPY COURT MARKHAM A6 L3R 5H6 ONTARIO, CANADA true true 0001702636 Lumira Capital Investment Management Inc. 141 ADELAIDE STREET WEST SUITE 770 TORONTO A6 M5H 3L5 ONTARIO, CANADA true true Common Shares 2020-01-08 4 P false 128722 3.20 A 1833066 I Held by Lumira Capital II, L.P. Common Shares 2020-01-08 4 P false 11903 3.20 A 169502 I Held by Lumira Capital II (International), L.P. Common Share Warrants (Right to Buy) 4.80 2020-01-08 4 P false 96542 A 2020-07-08 2023-07-08 Common Shares 96542 96542 I Held by Lumira Capital II, L.P. Common Share Warrants (Right to Buy) 4.80 2020-01-08 4 P false 8928 A 2020-07-08 2023-07-08 Common Shares 8928 8928 I Held by Lumira Capital II (International), L.P. Common Share Warrants (Right to Buy) 4.00 2020-01-08 4 P false 64362 A 2020-07-08 2020-11-08 Common Shares 64362 64362 I Held by Lumira Capital II, L.P. Common Share Warrants (Right to Buy) 4.00 2020-01-08 4 P false 5952 A 2020-07-08 2020-11-08 Common Shares 5952 5952 I Held by Lumira Capital II (International), L.P. The reported securities are included within 128,722 Common Shares purchased by the reporting person for $3.20 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share. The reported securities are included within 11,903 Common Shares purchased by the reporting person for $3.20 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share. This Form 4 is jointly filed by (i) Lumira Capital II, L.P. ("LCII LP"), (ii) Lumira Capital II (International), L.P. ("LCII INT LP"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023. Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020. /s/ Peter van der Velden 2020-01-10 /s/ Vasco Larcina 2020-01-10